A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases

Key facts

Sponsor

Beijing GoBroad Hospital

Intervention

OL-CD19-GDT(biological)

Enrollment

44 enrolled

Eligibility

18-65 years · All sexes

Timeline

2025 – 2028

Study locations (1)

• Beijing GoBroad Hospital, Beijing, China

Collaborators

Overland Therapeutics

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Systemic sclerosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07402226
  Systemic Sclerosis DIet for GastrointESTinal Symptoms
  University of Michigan
• RECRUITINGEARLY PHASE1NCT07355972
  Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC
  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
• RECRUITINGNANCT07360808
  Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis
  Cytori Therapeutics
• RECRUITINGNCT07228429
  Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images
  Yale University
• RECRUITINGEARLY PHASE1NCT07000682
  The Clinical Study on the Treatment of SSc With UTAA91 Injection.
  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
• RECRUITINGNCT06865118
  Home-Based Clinical Management of Cardiac Complications in Systemic Sclerosis
  Oslo University Hospital
• RECRUITINGNANCT06675344
  The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
  Robyn T. Domsic, MD, MPH
• RECRUITINGEARLY PHASE1NCT06775912
  Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
  Nanjing Bioheng Biotech Co., Ltd.

See all trials for Systemic sclerosis →